Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.61 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.61 |
| ▸ | NCF1 | P14598 | 2/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31285386 | 1.00 | NR4A2 (0.61) | NR4A2SOS2NCF1ALKCYP1A2 | |
| SCHEMBL436939 | 0.84 | NR4A2 (0.61) | NR4A2SOS2NCF1CYP1A2CYP2C19 | |
| SCHEMBL4470963 | 0.79 | ALK (0.53) | NR4A2SOS2NCF1ALKCYP1A2 | |
| SCHEMBL29896720 | 0.79 | ALK (0.53) | NR4A2SOS2NCF1ALKCYP1A2 | |
| SCHEMBL3073397 | 0.79 | NR4A2 (0.66) | NR4A2SOS2NCF1HTTPDPK1 | |
| SCHEMBL30044428 | 0.79 | NR4A2 (0.66) | NR4A2SOS2NCF1HTTPDPK1 | |
| Bromide SCHEMBL11522045 | 0.78 | ALK (0.51) | NR4A2SOS2NCF1ALKCYP1A2 | |
| SCHEMBL16247976 | 0.76 | ALK (0.50) | NR4A2SOS2NCF1ALKCYP1A2 | |
| SCHEMBL19878153 | 0.76 | ALK (0.50) | NCF1ALKCYP1A2CYP2C19HTT | |
| SCHEMBL1490718 | 0.76 | ALK (0.50) | NCF1ALKCYP1A2CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065166-A1 | Bone Modulators And Methods Therewith | ESPINA VIRGINIA (US) | 2012-03-15 | — | — | US | claimed |
| EP-4567032-A1 | KIF18A INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| CN-119731163-A | KIF18A inhibitor compound, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2025-03-28 | — | — | CN | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4353235-A2 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024051755-A1 | KIF18A INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-03-14 | — | — | WO | disclosed |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-112521387-B | NLRP3 modulators | 先天肿瘤免疫公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-4167982-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3351543-A1 | 1-(QUINOLIN-4-YL)-3-(6-(TRIFLUOROMETHYL)-PYRIDIN-2-YL)UREA AND 1-(QUINOLIN-4-YL)-3-(6-(TRIFLUOROMETHYL)-PYRAZINE-2-YL)UREA DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 (GSK-3) INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-07-25 | — | — | EP | disclosed |
| US-9540370-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBVIE DEUTSCHLAND GMBH & CO., KG. (DE) | 2017-01-10 | — | — | US | disclosed |
| CN-103476766-B | Heterocyclic compound and they are as the purposes of glycogen synthase kinase-3 inhibitors | ABBVIE德国有限责任两合公司 | 2016-08-10 | — | — | CN | disclosed |
| US-20150274724-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-01 | — | — | US | disclosed |
| US-9090592-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-07-28 | — | — | US | disclosed |
| CN-103476766-A | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBOTT GMBH & CO KG | 2013-12-25 | — | — | CN | disclosed |
| EP-2658854-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Abbvie Deutschland GmbH & Co. KG (DE) | 2013-11-06 | — | — | EP | disclosed |
| WO-2012089828-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-07-05 | — | — | WO | disclosed |
| US-20120172376-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-20120065166-A1 | Bone Modulators And Methods Therewith | ESPINA VIRGINIA (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | NR4A2 232/4885SOS2 4356/4885NCF1 188/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | NR4A2 2014/4885SOS2 1255/4885NCF1 374/4885 |
| US-20150274724-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | NR4A2 3713/4885SOS2 1646/4885NCF1 3432/4885 |
| US-20120172376-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | NR4A2 3713/4885SOS2 1646/4885NCF1 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.